

NeuroPace Inc. (NPCE)

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001528287

NeuroPace Inc. NPCE; healthcare	
Grade	B A B C D E second fifth of 371 graded peers percentile 25.1; sampling error 2.5 points; lower is stronger
Rank	94 of 371
Profitability	B percentile 28.3
Solvency	C percentile 51.3
Growth and financing	B/C percentile 39.8
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$12.5M to \$120M assets total assets \$105.6M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: fortress balance sheet
Inputs computable	9 of 14
Graded from	filings received through Mar 3, 2026 220 days before the rescan; latest periodic filing 10-Q received Aug 11, 2026
Last close	\$12.39 2026-10-08; market equity \$425.3M
Price used in grade	None



B, the elk

second fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescan

split-adjusted close; the letter is fixed at the rescan that set it



Rescans on file: B/C from Mar 21, 2025, B from Aug 21, 2025, B/C from Feb 21, 2026, B from Mar 21, 2026

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 3, 2026

We are a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Our novel and differentiated RNS System is the first and only commercially available, brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 28.3						
Gross profitability		73.1%	32.2%	11.6	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(10.4%)	(6.6%)	40.2	811	2025-12-31
Gross margin stability, five years		1.9 pts	2.8 pts	33.1	243	2025-12-31
Solvency, sleeve percentile 51.3						
Twelve-month failure probability		0.08%	0.07%	52.6	248	2026-06-30
Altman Z double-prime		(13.13)	(0.31)	67.0	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		5.28x	2.96x	34.1	839	2025-12-31
Growth and financing, sleeve percentile 39.8						
Revenue growth, three-year compound		30.0%	10.0%	21.7	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		(2.6%)	2.1%	57.9	704	2025-12-31
Net share issuance, one year		3.4%	2.5%	39.7	634	2026-02-27

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
------	---------	------------	--------	----------

89	Avalo Therapeutics, Inc. (AVTX)	23.8	B	dilution, degenerate inputs
90	Sarepta Therapeutics, Inc. (SRPT)	24.1	B	
91	Pulmonx Corp. (LUNG)	24.3	B	fortress balance sheet
92	Amphastar Pharmaceuticals, Inc. (AMPH)	24.6	B	
93	Mannatech Inc. (MTEx)	24.9	B	late filer, fortress balance sheet
94	NeuroPace Inc. (NPCE) <	25.1	B	
95	Zoetis Inc. (ZTS)	25.4	B	
96	Mirum Pharmaceuticals, Inc. (MIRM)	25.7	B	
97	Phibro Animal Health Corp. (PAHC)	25.9	B	
98	GE HealthCare Technologies Inc. (GEHC)	26.2	B	
99	Sensus Healthcare, Inc. (SRTS)	26.5	B	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	42.1%	8.0%	71
Distance from 52-week high	(35.8%)	(31.4%)	42
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(2.7%)	(1.0%)	46
Book value to price	0.03	0.28	15
Sales to price	0.24	0.31	42
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	0.14	(0.14)	71

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 5 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$12.5M
Operating cash flow, four quarters	-\$11.2M
Months of runway	13.4
Days since last periodic filing	59 (10-Q received Aug 11, 2026)
Median daily dollar volume, 63 sessions	\$2.1M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$77.2M	2025-12-31	2026-03-03	10-K	0001528287-26-000011
2	assets	us-gaap:Assets	\$105.6M	2025-12-31	2026-03-03	10-K	0001528287-26-000011
3	net income	us-gaap:NetIncomeLoss	-\$21.5M	2025-12-31	2026-03-03	10-K	0001528287-26-000011
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$11.0M	2025-12-31	2026-03-03	10-K	0001528287-26-000011

5	assets	us-gaap:Assets	\$94.6M	2024-12-31	2026-03-03	10-K	0001528287-26-000011
6	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$100.0M	2025-12-31	2026-03-03	10-K	0001528287-26-000011
7	gross profit	us-gaap:GrossProfit	\$59.1M	2024-12-31	2026-03-03	10-K	0001528287-26-000011
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$79.9M	2024-12-31	2026-03-03	10-K	0001528287-26-000011
9	gross profit	us-gaap:GrossProfit	\$48.1M	2023-12-31	2025-03-04	10-K	0001528287-25-000007
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$65.4M	2023-12-31	2025-03-04	10-K	0001528287-25-000007
11	gross profit	us-gaap:GrossProfit	\$32.5M	2022-12-31	2024-03-05	10-K	0001528287-24-000005
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$45.5M	2022-12-31	2024-03-05	10-K	0001528287-24-000005
13	gross profit	us-gaap:GrossProfit	\$33.4M	2021-12-31	2023-03-02	10-K	0001528287-23-000007
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$45.2M	2021-12-31	2023-03-02	10-K	0001528287-23-000007
15	current assets	us-gaap:AssetsCurrent	\$94.1M	2025-12-31	2026-03-03	10-K	0001528287-26-000011
16	current liabilities	us-gaap:LiabilitiesCurrent	\$17.8M	2025-12-31	2026-03-03	10-K	0001528287-26-000011
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$552.4M	2025-12-31	2026-03-03	10-K	0001528287-26-000011
18	operating income	us-gaap:OperatingIncomeLoss	-\$16.3M	2025-12-31	2026-03-03	10-K	0001528287-26-000011
19	book equity	us-gaap:StockholdersEquity	\$19.0M	2025-12-31	2026-03-03	10-K	0001528287-26-000011
20	liabilities	us-gaap:Liabilities	\$86.5M	2025-12-31	2026-03-03	10-K	0001528287-26-000011
21	operating income	us-gaap:OperatingIncomeLoss	-\$27.2M	2023-12-31	2025-03-04	10-K	0001528287-25-000007
22	interest expense	us-gaap:InterestExpense	\$8.5M	2023-12-31	2024-03-05	10-K	0001528287-24-000005
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$332,000	2025-12-31	2026-03-03	10-K	0001528287-26-000011
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$17.9M	2024-12-31	2026-03-03	10-K	0001528287-26-000011
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$306,000	2024-12-31	2026-03-03	10-K	0001528287-26-000011
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$19.7M	2023-12-31	2025-03-04	10-K	0001528287-25-000007
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$173,000	2023-12-31	2025-03-04	10-K	0001528287-25-000007
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$36.9M	2022-12-31	2024-03-05	10-K	0001528287-24-000005
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$603,000	2022-12-31	2024-03-05	10-K	0001528287-24-000005
30	assets	us-gaap:Assets	\$107.7M	2023-12-31	2025-03-04	10-K	0001528287-25-000007
31	assets	us-gaap:Assets	\$114.1M	2022-12-31	2024-03-05	10-K	0001528287-24-000005
32	shares outstanding	dei:EntityCommonStockSharesOutstanding	33,666,948	2026-02-27	2026-03-03	10-K	0001528287-26-000011
33	shares outstanding	dei:EntityCommonStockSharesOutstanding	32,560,130	2025-02-28	2025-03-04	10-K	0001528287-25-000007